Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Needham & Company Raises Price Target on Rogers (ROG) to $75 Following Solid 3Q
November 4, 2016 8:26 AM EDTNeedham & Company reiterated a Buy rating on Rogers Corp (NYSE: ROG), and raised the price target to $75.00 (from $70.00), following the company's 3Q earnings report. ROG reported revenues of $165M and EPS of $0.95, above prior guidance for $150-160M and adjusted EPS of $0.69-0.79. Previous consensus... More
Genentech (RHHBY) to Make 60+ Presentations at ASH 2016; Will Include Phase III GALLIUM Study Data
November 3, 2016 12:39 PM EDTGenentech, a member of the Roche Group (OTC: RHHBY), announced that more than 60 abstracts featuring nine of its approved or investigational medicines will be presented during the 58th American Society of Hematology (ASH) Annual Meeting from December 3-6 in San Diego. The abstracts include more than 20 oral presentations across a broad range of medicines and combinations.
The breadth of data we are presenting at ASH this year reflects our deep commitment to people with blood diseases, said Sandra Horning, M.D., chief medical officer and head of Global Product Development. We are... More
Rogers (ROG) Tops Q3 EPS by 20c
November 2, 2016 5:45 PM EDTRogers (NYSE: ROG) reported Q3 EPS of $0.88, $0.20 better than the analyst estimate of $0.68. Revenue for the quarter came in at $165.3 million versus the consensus estimate of $154.02 million.
For earnings history and earnings-related data on Rogers (ROG) click here.
... More